New research shows HAND2 gene methylation may have potential as a biomarker for early endometrial cancer detection and as a predictor of treatment response.
An intrauterine device (IUD) is an effective tool in the treatment of early-stage endometrial cancer in certain patients, according to the results of a small study presented at the International Gynecological Cancer Society’s 14th biennial meeting.
A review comparing laparoscopic hysterectomy versus abdominal hysterectomy for early-stage endometrial cancer has found that rates of overall survival and disease-free survival are similar for the surgical procedures.
Researchers in France have developed a nomogram based on pathological hysterectomy characteristics to predict lymph node metastasis in patients with endometrial cancer.
Obesity does not impact perioperative outcomes in women undergoing robotic hysterectomy, according to a recent study.
Laparoscopy has short-term advantages and seemingly equivalent long-term outcomes as compared with laparotomy for endometrial cancer according to a meta-analysis of randomized controlled trials.
Laparoscopic staging of uterine cancer is associated with only a small increased risk of recurrence, according to a new study in the Journal of Clinical Oncology.
Based on the protective effects of intrauterine devices against endometrial cancer, researchers hypothesized that IUDs may also have a protective effect against cervical cancer. However, results from epidemiological and clinical studies to date have been inconclusive.
Endometrial stromal sarcoma (ESS) is a rare malignant tumor of the endometrium, occurring in the age group of 40-50 years.
Endometrial cancer remains the most commonly diagnosed gynecologic cancer in the United States. In fact, the number of women affected by the disease continues to rise despite a slight decline in annual incidence rates in the past 30 years.